December 22, 2023 07:17 AM ESTUpdated 07:31 AM
Deals
Pharma

Bris­tol My­ers bets on neu­ro­science surge with $14B Karuna cash ac­qui­si­tion

Kyle LaHucik

Senior Reporter

Bris­tol My­ers Squibb will buy CNS drug­mak­er Karuna Ther­a­peu­tics for cash in a deal val­ued at $14 bil­lion, the com­pa­nies

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Trump ad­min­is­tra­tion re­veals 'most fa­vored na­tion' drug price coun­try tar­gets

In his first ma­jor pol­i­cy roll­out, Vinay Prasad looks to chal­lenge ex­ist­ing 'dog­ma' on Covid vac­cines

Up­dat­ed: FDA ad­comm splits votes on Genen­tech and J&J can­cer drugs

RFK Jr. spars with sen­a­tors over re­search cuts, HHS bud­get plan

CRISPR Ther­a­peu­tics part­ners with siR­NA com­pa­ny, show­ing that gene edit­ing isn’t the on­ly an­swer

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times